Whoever you are, Pearl has a story to share:
Your life uninterrupted
Discover the innovative method that helps you avoid the risks, pain, and long recovery of major joint replacement surgery.
Pearl - mechanism of action
Pearl is addressing a critical medical need for young, active patients with early to moderate cartilage lesions, for whom currently available treatment options do not consistently achieve cartilage regeneration or long-term preservation of the native joint.
Innovation as it stands
At ArThec we are leveraging proprietary technology to deliver the first curative solution for osteoarthritis, secured by robust intellectual property.
Osteoarthritis.
Understanding The Disease.
Osteoarthritis is characterized by the progressive and irreversible loss of joint cartilage. Worldwide, 80% of sufferers experience limited movement due to the progressive and irreversible loss of joint cartilage. In advanced stages, this necessitates joint replacement.
Pearl brings the joint back to its healthy state, before any injury or disease occurred. The procedure is characterized by reduced invasiveness and aims for faster recovery. The implanted material is formed cartilage with the full histological, biochemical, and mechanical properties of native tissue, ensuring natural integration.
We enable the cultivation of full-thick, stable but also flexible cartilage in vitro that biologically restores the functions of the joint.
Discover the innovative method that helps you avoid the risks, pain, and long recovery of major joint replacement surgery.
Pearl method.
Mechanism of Action & Clinical Superiority.
Pearl is based on a tissue-engineered approach that delivers structured cartilage tissue rather than isolated cells. This design avoids reliance on cell suspensions or animal-derived matrices and is intended to provide a well-organised cartilage construct at the time of implantation.
The final product is characterised by histological organisation and biochemical and mechanical properties comparable to native cartilage tissue, supporting tissue stability, elasticity, and integration within the joint environment.
The procedure utilises ArThec’s proprietary devices, including a dedicated trocar designed to very safe and efficient tissue harvesting while preserving surrounding structures. The process is standardised and can be performed by trained personnel in appropriately certified laboratories.
What do professionals think?
The final product possesses full histological, biochemical, and mechanical properties of native cartilage tissue, ensuring stability, elasticity, resistance to friction/compression, and natural integration with surrounding tissue.
The procedure can be reliably performed by appropriately trained personnel and is not limited by location, allowing it to be conducted in any suitably certified facility.
ArThec innovation.
Pioneering the Future of Regenerative Joint Medicine.
ArThec designed the first technology in history capable of regenerating the joint back to its original health, prior to injury or disease.
We address a critical medical need by offering a regenerative treatment for patients with cartilage damage—whether trauma-related or degenerative. Pearl helps restore durable joint function and halt further deterioration, providing particular long-term benefit to younger patients for whom joint replacement carries significant future risks.
Pearl is an ATMP therapy combined with innovative ArThec-developed medical devices and dedicated equipment that supports product manufacturing under GMP conditions.
Our core technology is already protected by patents in multiple countries, and as a company driven by innovation, we are constantly developing new technologies and therapies to better support patients.
Meet ArThec Team.
Marek Putko, MBA
CEO
A leader with over thirty years of experience in sales and marketing management, with hands-on expertise in project development and the implementation of sales strategies. He possesses extensive market knowledge gained through work with leading international corporations as well as domestic medical and pharmaceutical companies.
Dr Sławomir Jaros, EMBA
Co–Founder, CSO, CQO
Biotechnology and biopharmaceutical leader with over two decades of experience integrating science, innovation, and executive management. He has led cross-functional areas including R&D, GMP manufacturing, QC/QA, regulatory and clinical activities, supporting programs from early development through late-stage and commercial operations.
Grzegorz Sobieraj, MD
Co–Founder, Supervisory Board Member, Principal Investigator
Specialist in orthopedics and traumatology of the musculoskeletal system. He holds clinical leadership roles, including heading the orthopedic ward at Ortho Sport Clinic and serving as Medical Director at the St. John of God (Bonifraters) hospital in Łódź, with additional management experience in an orthopedic department in Brzeziny. He is affiliated with major professional societies (e.g., ESSKA, ICRS, Polish Arthroscopic Society, Polish Orthopedic Society).
